The MHRA has tightened rules on the use of the Chikungunya vaccine, IXCHIQ, following recommendations by the Commission on Human Medicines (CHM). The vaccine is now restricted to adults aged 18 to 59 years and should not be administered to individuals over 60 or those with specific health conditions. These conditions include high blood pressure, heart disease, diabetes, chronic kidney disease, immunodeficiency, or immunosuppression. The CHM concluded that the benefits of vaccination remain favorable for at-risk individuals aged 18-59 without these conditions. Healthcare professionals must conduct a comprehensive benefit-risk assessment before offering the vaccine, especially for those with multiple chronic health issues. The vaccine should be administered at least 30 days before travel to ensure access to healthcare in the UK. The decision is based on global safety data, with 28 cases of serious adverse reactions reported, three of which were fatal. Chikungunya virus is prevalent in subtropical regions and spreads through mosquito bites, not person-to-person contact. Symptoms typically resolve within 7-10 days, and most patients recover fully. The MHRA's decision reflects a permanent restriction on vaccine use, as outlined in the Drug Safety Update, and will be updated in the Patient Information Leaflet. The MHRA emphasizes its role in regulating medicines and medical devices, ensuring their safety and effectiveness, and invites individuals to report any vaccine side effects to the Yellow Card scheme.
